Fungal Infections

Proceedings of the American Thoracic Society

Volumn 3, Issue 1, 2006, Pages 35-40

  Kauffman, Carol A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Asperigillosis; Candidiasis; Echinocandins; Triazoles; Zygomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CASPOFUNGIN; CYCLODEXTRIN; CYCLOSPORIN; ECHINOCANDIN; ERGOT ALKALOID; FLUCONAZOLE; MICAFUNGIN; PHENYTOIN; PYRROLE DERIVATIVE; RAPAMYCIN; RIFAMPICIN; TSUKUBAENOLIDE; VORICONAZOLE; WARFARIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANTIBIOTIC RESISTANCE; ASPERGILLOSIS; ASPERGILLUS; BLURRED VISION; CANDIDA; CANDIDIASIS; CELL DAMAGE; CHILL; CLINICAL TRIAL; COLOR DISCRIMINATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FUSARIUM; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HOT FLUSH; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; INTENSIVE CARE UNIT; LIVER TOXICITY; MOULD; MUCOR; MYCOSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PHLEBITIS; PHOTOPSIA; PHOTOSENSITIVITY; PNEUMONIA; PRURITUS; REVIEW; RHIZOPUS; SCEDOSPORIUM; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; ZYGOMYCETES;

ANTIFUNGAL AGENTS; DIAGNOSIS, DIFFERENTIAL; FUNGI; HUMANS; MYCOSES;

EID: 33644545075     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200510-110JH     Document Type: Review

References (43)

1. Pappas PG, Rex JH, Lee J,Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:634-643.
2. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, Pfaller M, Edwards JE, Jarvis W, Dawson J, et al. National epidemiology of mycoses survey (NEMIS): variations in rate of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999;29:253-258.
3. Michalopoulos AS, Geroulanos S, Mentzelopolous SD. Determinants of candidemia and candidemia-related deaths in cardiothoracic ICU patients. Chest 2003;124:2244-2255.
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317.
5. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2004;37:1172-1177.
6. Baddley JW, Smith AM, Moser SA, Pappas PG. Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a university hospital. Diagn Microbiol Infect Dis 2001;39:199-201.
7. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-1128.
8. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309-316.
9. Malani PN, Bradley SF, Little RS, Kauffman CA. Trends in species causing fungaemia in a tertiary care medical centre over 12 years. Mycoses 2001;44:446-449.
10. Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, Pfaller MA. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study. J Clin Microbiol 2002;40:1298-1302.
11. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-189.
12. Rex JH, Bennett JE, Sugar AM, Pappas PG, Van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-1330.
13. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-2029.
14. Rex JH, Bennett JE, Sugar AM. Intravascular catheter exchanges and the duration of candidemia. Clin Infect Dis 1995;21:994-996.
15. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW,Morrison VA, Pappas P, Hiemenz JW, Stevens DA. The impact of culture isolation of Aspergillus: a hospital-based survey of aspergillosis. Clin Infect Dis 2001;33:1824-1833.
16. Steinbach WJ, Benjamin DK, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004;39:192-198.
17. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005;41:521-526.
18. Castiglioni B, Sutton DA, Rinaldi MG, Fung J, Kusne S. Pseudallescheria boydii (anamorph Scedosporium apiospermum) infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) 2002;81:333-348.
19. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917.
20. Berenguer J, Rodriquez-Tudela JL, Richard C, Alvaer M, Sanz MA, Gaztelurrutaia L, Ayats J, Martinez-Suarez JV, et al. Deep infections caused by Scedosporium prolificans: a report on 16 cases in Spain and a review of the literature. Medicine (Baltimore) 1997;76:256-265.
21. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignany: ten years experience at a cancer center and implications for management. Blood 1997;90:999-1008.
22. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-653.
23. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996;100:171-178.
24. Caillot D, Casasnovas O, Bernard A, Couaillier J-F, Durand C, Cuisenier B, Solary E, Piard F, Petralla T, Bonnin A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-147.
25. Caillot D, Couailler J-F, Benard A, Casanovas O, Denning DW, Mannone L, Lopez J, Couillault G, Piard F, Vagner O, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001;19:253-259.
26. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-366.
27. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, Kern WV, Marr KA, Ribaud P, Lortholary O, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
28. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240-248.
29. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563-1571.
30. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797-802.
31. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-637.
32. Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 2002;11:409-429.
33. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003;37:728-732.
34. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002;46:3091-3093.
35. Romero AJ, Le Pogamp P, Nilsson L-G, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226-234.
36. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-571.
37. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002;35:1273-1275.
38. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rey JH, Cleary JD, Rubinstein E, Church LWP, Brown JM, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized noninferiority trial. Lancet 2005;366:1435-1442.
39. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36:1445-1457.
40. Ullmann AJ. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 2003;19:263-271.
41. Sable CA, Nguyen BY, Chodakewitz JA,DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002;4:25-30.
42. Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003;97:1025-1032.
43. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GL, Raad II. Efficacy and toxicity of caspofungin in combination with amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003;98:292-299.